Spyre Therapeutics Stock Alpha and Beta Analysis
| SYRE Stock | 27.70 0.70 2.59% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Spyre Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Spyre Therapeutics over a specified time horizon. Remember, high Spyre Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Spyre Therapeutics' market risk premium analysis include:
Beta 2.37 | Alpha (0.06) | Risk 3.68 | Sharpe Ratio 0.0167 | Expected Return 0.0615 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Spyre |
Spyre Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Spyre Therapeutics market risk premium is the additional return an investor will receive from holding Spyre Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Spyre Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Spyre Therapeutics' performance over market.| α | -0.06 | β | 2.37 |
Spyre Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Spyre Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Spyre Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Spyre Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Spyre Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Spyre Therapeutics shares will generate the highest return on investment. By understating and applying Spyre Therapeutics stock market price indicators, traders can identify Spyre Therapeutics position entry and exit signals to maximize returns.
Spyre Therapeutics Return and Market Media
The median price of Spyre Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 29.06 with a coefficient of variation of 11.2. The daily time series for the period is distributed with a sample standard deviation of 3.4, arithmetic mean of 30.39, and mean deviation of 2.83. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 18531 shares by Scott Burrows of Spyre Therapeutics at 28.173 subject to Rule 16b-3 | 09/03/2024 |
2 | Spyre Therapeutics Shares Gap Down to 30.17 - MarketBeat | 09/23/2024 |
3 | Perceptive Advisors LLC Increases Stake in Spyre Therapeutics, Inc. - MarketBeat | 09/30/2024 |
4 | Syre Exec Says Its Inflection Point Time for TextileCircularity | 10/04/2024 |
5 | Acquisition by Sloan Sheldon of 400000 shares of Spyre Therapeutics at 27.46 subject to Rule 16b-3 | 10/16/2024 |
6 | Disposition of 300 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.43 subject to Rule 16b-3 | 10/25/2024 |
7 | Spyre Therapeutics director sells shares worth 10,929 | 10/28/2024 |
8 | Disposition of 6700 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.7631 subject to Rule 16b-3 | 11/06/2024 |
9 | Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/07/2024 |
10 | Spyre shares target raised to 71 on positive trial data | 11/12/2024 |
11 | Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc | 11/15/2024 |
12 | Spyre Therapeutics announces proposed secondary offering | 11/18/2024 |
13 | Fairmount Funds Management LLCs Strategic Acquisition in Oruka Therapeutics Inc | 11/22/2024 |
About Spyre Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Spyre or other stocks. Alpha measures the amount that position in Spyre Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 58.77 | 67.59 | 106.24 | PTB Ratio | 0.75 | 0.81 | 0.77 |
Spyre Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Spyre Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spyre Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Spyre Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Spyre Therapeutics. Please utilize our Beneish M Score to check the likelihood of Spyre Therapeutics' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Spyre Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Spyre Therapeutics Backtesting, Spyre Therapeutics Valuation, Spyre Therapeutics Correlation, Spyre Therapeutics Hype Analysis, Spyre Therapeutics Volatility, Spyre Therapeutics History and analyze Spyre Therapeutics Performance. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Spyre Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.